Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375297 | 0.84 | MAPT (0.50) | KMT2AMEN1ALDH1A1L3MBTL1GLA | |
| SCHEMBL6772054 | 0.82 | DPP8 (0.48) | KMT2AMEN1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL2510372 | 0.78 | KMT2A (0.56) | KMT2AMEN1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL21887012 | 0.76 | ALDH1A1 (0.55) | KMT2AMEN1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL15610829 | 0.76 | KMT2A (0.54) | KMT2AMEN1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL874787 | 0.76 | TSHR (0.51) | — | |
| SCHEMBL4196572 | 0.75 | ALDH1A1 (0.53) | KMT2AMEN1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL10805478 | 0.75 | MAPT (0.58) | KMT2AMEN1ALDH1A1GLAMAPT | |
| SCHEMBL7824219 | 0.75 | ALDH1A1 (0.53) | KMT2AMEN1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL17811731 | 0.74 | ALDH1A1 (0.52) | KMT2AMEN1OPRM1OPRD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | KMT2A 2366/4885MEN1 2288/4885OPRM1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.